Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 147: | Line 147: | ||
[https://www.nature.com/articles/s41541-020-0196-3 by Patrick E. Duffy 9/6/20 npj] | [https://www.nature.com/articles/s41541-020-0196-3 by Patrick E. Duffy 9/6/20 npj] | ||
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic Plasmodium falciparum candidate RTS,S was favorably reviewed by the European Medicines Agency and subsequently introduced into national pilot implementation programs, marking the first human anti-parasite vaccine to pass regulatory scrutiny. | Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic Plasmodium falciparum candidate RTS,S was favorably reviewed by the European Medicines Agency and subsequently introduced into national pilot implementation programs, marking the first human anti-parasite vaccine to pass regulatory scrutiny. | ||
=====Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria===== | |||
[https://www.nature.com/articles/s41541-020-00259-3 by David C. Kaslow 20/11/20 npj] | |||
This collection of malaria vaccine research and innovation papers highlights the intersection of efforts to: (1) achieve the pan-African1 and global goal2 of “Zero Malaria”; and (2) make the compelling case for immunization3 as a set of new tools for malaria control and elimination. | |||
